AbCellera Biologics (ABCL) Current Taxes (2020 - 2022)

AbCellera Biologics (ABCL) has 3 years of Current Taxes data on file, last reported at $23.0 million in Q3 2022.

• Quarterly Current Taxes rose 249.29% year-over-year to $23.0 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $23.0 million (up 249.29% YoY) and the FY2021 annual result came in at $35.7 million, down 1.3% from the prior year.
• Current Taxes slipped to $23.0 million in Q3 2022, from $107.3 million in the prior quarter.
• In the past five years, Current Taxes ranged from a high of $107.3 million in Q2 2022 to a low of $5.8 million in Q2 2021.
• A 3-year average of $43.8 million and a median of $32.9 million in 2021 frame the typical range for Current Taxes.
• Annual changes were most pronounced in 2021 — Current Taxes retreated 1.3% — and 2022, when it surged 1743.39%.
• Tracing ABCL's Current Taxes over 3 years: stood at $36.2 million in 2020, then retreated by 1.3% to $35.7 million in 2021, then tumbled by 35.49% to $23.0 million in 2022.
• The last three Current Taxes figures came in at $23.0 million (Q3 2022), $107.3 million (Q2 2022), and $105.6 million (Q1 2022), per Business Quant data.